I’ll forgive you for thinking I’m taking the piss because I’ve been a Washer and Macdonald knocker but I’m genuinely asking because this announcement seems very good.
How can CYP not have Osteoarthritis on their radar at all up to and including an investor presentation in Nov 2018 but then out of the blue announce a Phase2 OA trial in Dec 2018, and now upgrade the trial to be a Phase 3.
This is all without any testing to get dosing levels calibrated and observing early efficacy signs that are common for a Phase 1 trial. No phase 1, straight to Phase 3, it sounds awesome but surely there must be some issues here??
Ann: Ethics Approval & Expedited Pathway for Phase 3 OA Trial, page-23
-
- There are more pages in this discussion • 473 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.005(1.82%) |
Mkt cap ! $48.78M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.5¢ | 26.5¢ | $71.17K | 257.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 145786 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |